- Full Year 2023 Transgene SA Earnings Call TranscriptMar 27, 2024€1.08 (-0.55%)Earnings
- Half Year 2023 Transgene SA Earnings Call TranscriptSep 20, 2023€1.81 (+1.80%)Earnings
- Transgene SA Conference Call TranscriptMay 05, 2023
- Full Year 2022 Transgene SA Earnings Call TranscriptMar 16, 2023€1.91 (-1.55%)Earnings
- Transgene SA Interim Analysis of TG4001 Phase II Trial Call TranscriptNov 02, 2022
- Transgene SA R&D Day TranscriptSep 27, 2022
- Q2 2022 Transgene SA Earnings Call TranscriptSep 07, 2022€2.06 (+0.49%)Earnings
- Q4 2021 Transgene SA Earnings Call TranscriptMar 16, 2022€2.22 (+6.47%)Earnings
- Transgene SA Corporate Call TranscriptDec 15, 2021
- Transgene SA TG4050 Phase I Studies Results Webcast TranscriptNov 23, 2021
- Q2 2021 Transgene SA Earnings Call TranscriptSep 22, 2021€2.41 (+1.26%)Earnings
- Transgene SA Presents Results From the Phase 1b/2 trial of TG4001 in Combination with Avelumab Conference Call TranscriptNov 12, 2020
- Transgene SA Results from Clinical Study of TG4001 in Combination with Avelumab Conference Call TranscriptJul 22, 2020
- Q4 2019 Transgene SA Earnings Call TranscriptMar 11, 2020€1.23 (+6.59%)Earnings
Transgene SA Results from Clinical Study of TG4001 in Combination with Avelumab Conference Call Transcript
Hello, and welcome to the Transgene Reports Results from Clinical Study with TG4001. My name is Monique, and I'll be your coordinator for today's event. Please note, this call is being recorded. (Operator Instructions)
I will now hand you over to your host, Lucie Larguier, to begin today's conference. Thank you.
Thank you, Monique, and hello, everyone. So I'm here today on the call with Philippe Archinard, our Chairman and CEO; as well as Maud Bradley, our Chief Medical Officer. And we're very happy to be discussing with you the promising results that we obtained with TG4001 in combination with avelumab in our exploratory Phase Ib/II trial.
Before I turn over the call to Philippe, I'd like to remind everyone that today's discussion contains forward-looking statements, which are subject to numerous risks and uncertainties. So we would also like to remind you that this call is being recorded and that it will be available on our website.
The webcast can be
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)